FDA extends review of Abbvie's sNDA for Rinvoq in atopic dermatitis
- The FDA is extending the PDUFA data for Abbvie's (NYSE:ABBV) sNDA for the JAK inhibitor Rinvoq (upadacitinib) in moderate to severe atopic dermatitis by three months to Q3 2021.
- AbbVie previously disclosed it received an information request from the FDA for an updated assessment of the benefit-risk profile for the drug in this indication and it responded.
- Last month, Abbvie said the FDA was extending the PDUFA data for another Rinvoq sNDA in psoriatic arthritis to late Q2.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.